eMIMS New Product
New drug - Volibris
29-Jul-08
GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Class II and III) to improve exercise capacity.
Ambrisentan is an endothelin receptor antagonist that blocks the endothelin A receptor on vascular smooth muscle cells and cardiac myocytes, preventing vasoconstriction and smooth muscle cell proliferation.
The recommended dose of Volibris is 5mg once daily. Some additional efficacy has been observed with 10mg once daily in patients with class III symptoms, however an increase in peripheral oedema has also been observed.
Patients with associated connective tissue disease may require 10mg once daily.
Volibris is currently the only drug licensed for patients with class II pulmonary arterial hypertension.
Further information: GSK 0800 221441
Tools
Related Articles
Related Drugs By Area
Jobs
Job of the Week
- Salaried GP North West England
- Full Time Salaried GP
- GP Locum Regular / Long Term West Midlands
- Salaried GP Central London
- Full-Time Salaried GP Central London
- Full time Salaried GP West Midlands
- Partner North West England
- Registered Medical Practitioners
- GPs Australasia
- Locum GP West Midlands
Comments
Only registered users may comment. Log in now or register for a free account.
There are problems with your form submission.
Please review the errors shown below.